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Supplemental methods, figures, and tables
Expanded methods
Study design
The COMBI study (#EudraCT2013-003295-12) was an investigator-initiated, multicenter, open-label, singlearm phase II study; we included 50 patients: 32 with PV and 18 with MF. The study was conducted 2014-2018 at three sites in Denmark and approved by the Danish Regional Science Ethics Committee and the Danish Medicines Agency. It was done under the principles of the Declaration of Helsinki. Patients gave written informed consent.
Inclusion/exclusion criteria
Patients aged ≥18 years with a PV or MF diagnosis according to the 2008 WHO criteria were considered eligible, if they had evidence of active disease, defined as one or more of the following: need for phlebotomy, white blood cell count ≥10 10 9 /L, platelet count ≥400 10 9 /L, constitutional symptoms, pruritus, symptomatic splenomegaly, and previous thrombosis. Patients fulfilling one or more of the following criteria were excluded: pregnancy; allergic hypersensitivity to study medications; ECOG performance status ≥3; other active malignancy within five years; impaired renal or hepatic function; treatment with immunosuppressive drugs except corticosteroids within the preceding six months; psychiatric disease; severe neurological disease; uncontrolled metabolic disease; severe cardiac disease; white blood cell count <1.5 10 9 /L; and platelet count <100 10 9 /L.
Treatment schedule and dosing
Initiation of study treatment and baseline evaluations were preceded by a minimum seven-day wash-out period after discontinuation of any previous cytoreductive therapies. Patients were initially treated with PEG-IFNα2a (Pegasys®; Genentech (Roche), South San Francisco, CA, USA) 45 µg/week or PEG-IFNα2b medication was self-administered. Doses were modified at the investigators' discretion based on toxicity and efficacy.
Patient evaluations
Study visits were scheduled at baseline, two weeks, one month, three months, and every third month after that until two years of treatment. Each visit included documentation of adverse events, full-scale hematology, blood biochemistry investigations, Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) (1), and assessment of compliance by research staff. Bone marrow biopsies were done at baseline and after one and two years of treatment. Spleen size, measured as longest diameter by sonography, and JAK2 V617F or calreticulin (CALR) mutation measurements were done at baseline and after three months, six months, one year and two years. The proportion of JAK2 V617F and CALR mutated alleles were quantified using a high-sensitivity real-time qPCR on whole-blood with a lower detection limit of £0.1% (2, 3).
Endpoints
The primary outcome was efficacy, based on hematological parameters, quality of life measurements, and the JAK2 V617F burden. The 2013 ELN and IWG-MRT response criteria were used to assess efficacy (4, 5).
In brief, for patients with PV, achieving complete remission (CR) required resolution of disease-related symptoms and hepatosplenomegaly; peripheral blood count remission (PBCR), with a platelet count below 400 x 10 9 /L and white blood cell count < 10 x 10 9 /L and absence of leucoerythroblastosis; no progression of the disease and no hemorrhagic or thrombotic events; and bone marrow histological remission (BMHR), with age-adjusted normocellularity, and fibrosis grade ≤1. A partial remission (PR) required all the above except BMHR. A criterion for resolution of disease-related symptoms in patients with PV is 'large symptom improvement' defined as a ≥10-point decrease in MPN-SAF total symptom score (TSS). We modified this criterion for patients with a baseline TSS <10 (n=3). In these patients, durable TSS <10, and no disease-related symptoms reported at the study visit fulfilled the criteria.
For patients with MF, achieving CR required resolution of disease-related symptoms and hepatosplenomegaly; PBCR with hemoglobin ≥10 g/dL, neutrophil count ³ 1 x 10 9 , platelet count ³100 x 10 9 /L all below the
